Anthony Boral

8.8k total citations · 1 hit paper
59 papers, 2.6k citations indexed

About

Anthony Boral is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, Anthony Boral has authored 59 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 22 papers in Molecular Biology and 22 papers in Hematology. Recurrent topics in Anthony Boral's work include Multiple Myeloma Research and Treatments (22 papers), Lymphoma Diagnosis and Treatment (17 papers) and Lung Cancer Treatments and Mutations (17 papers). Anthony Boral is often cited by papers focused on Multiple Myeloma Research and Treatments (22 papers), Lymphoma Diagnosis and Treatment (17 papers) and Lung Cancer Treatments and Mutations (17 papers). Anthony Boral collaborates with scholars based in United States, Germany and Italy. Anthony Boral's co-authors include Sagar Lonial, André Goy, Edward A. Stadtmauer, Sven de Vos, Hongliang Shi, Richard I. Fisher, Steven H. Bernstein, Owen A. O’Connor, Brad S. Kahl and Michael J. Robertson and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Anthony Boral

59 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma

2006 553 citations Richard I. Fisher, Steven H. Bernstein et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anthony Boral United States	22	1.3k	1.3k	969	884	597	59	2.6k
Hongliang Shi United States	20	904 0.7×	941 0.7×	773 0.8×	703 0.8×	511 0.9×	44	2.0k
Alejandro Martı́n Spain	25	1.4k 1.0×	845 0.7×	909 0.9×	861 1.0×	533 0.9×	128	2.8k
Soham D. Puvvada United States	17	1.0k 0.8×	810 0.6×	489 0.5×	990 1.1×	1.1k 1.9×	59	2.6k
Francesco Turturro United States	19	637 0.5×	580 0.5×	412 0.4×	546 0.6×	253 0.4×	64	1.4k
Ellen Schlette United States	28	700 0.5×	701 0.6×	412 0.4×	1.3k 1.5×	1.3k 2.2×	69	2.3k
Stephen E. Spurgeon United States	25	690 0.5×	794 0.6×	543 0.6×	1.3k 1.5×	1.6k 2.7×	98	2.4k
Kathryn S. Kolibaba United States	22	1.4k 1.0×	710 0.6×	1.0k 1.0×	2.0k 2.3×	2.0k 3.3×	93	3.5k
Morten Mau‐Sørensen Denmark	28	1.2k 0.9×	1.1k 0.9×	258 0.3×	310 0.4×	570 1.0×	130	2.7k
Enrico Tiacci Italy	27	703 0.5×	1.1k 0.9×	811 0.8×	1.1k 1.2×	1.1k 1.8×	77	2.8k
Leslie A. Andritsos United States	30	1.0k 0.8×	967 0.8×	866 0.9×	1.5k 1.7×	2.1k 3.4×	161	3.5k

Countries citing papers authored by Anthony Boral

Since Specialization

Citations

This map shows the geographic impact of Anthony Boral's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anthony Boral with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anthony Boral more than expected).

Fields of papers citing papers by Anthony Boral

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anthony Boral. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anthony Boral. The network helps show where Anthony Boral may publish in the future.

Co-authorship network of co-authors of Anthony Boral

This figure shows the co-authorship network connecting the top 25 collaborators of Anthony Boral. A scholar is included among the top collaborators of Anthony Boral based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anthony Boral. Anthony Boral is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shields, Alan L., Fiona Taylor, Roger E. Lamoureux, et al.. (2023). Psychometric evaluation of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF©) and determination of a threshold score for moderate symptoms. Orphanet Journal of Rare Diseases. 18(1). 69–69. 3 indexed citations

Taylor, Fiona, Xiaoran Li, Christine Yip, et al.. (2021). Psychometric evaluation of the Advanced Systemic Mastocytosis Symptom Assessment Form (AdvSM-SAF). Leukemia Research. 108. 106606–106606. 5 indexed citations

Shields, Alan L., Fiona Taylor, Xiaoran Li, et al.. (2021). Psychometric evaluation of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF) in a phase 2 clinical study. Orphanet Journal of Rare Diseases. 16(1). 434–434. 8 indexed citations

Taylor, Fiona, Cem Akin, Roger E. Lamoureux, et al.. (2021). Development of symptom-focused outcome measures for advanced and indolent systemic mastocytosis: the AdvSM-SAF and ISM-SAF©. Orphanet Journal of Rare Diseases. 16(1). 414–414. 9 indexed citations

Mehren, Margaret von, Michael C. Heinrich, Hongliang Shi, et al.. (2018). A retrospective natural history study of patients (pts) with PDGFRα D842V mutant advanced gastrointestinal stromal tumor (GIST) previously treated with a tyrosine kinase inhibitor (TKI).. Journal of Clinical Oncology. 36(15_suppl). 11533–11533. 2 indexed citations

Nishio, Makoto, Haruyasu Murakami, Atsushi Horiike, et al.. (2015). Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non–Small-Cell Lung Cancer or Other Tumors. Journal of Thoracic Oncology. 10(7). 1058–1066. 58 indexed citations

Tan, Daniel Shao-Weng, Alice T. Shaw, Ranee Mehra, et al.. (2014). Ceritinib in Asian versus Caucasian patients (Pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) NSCLC: Subgroup analysis of the ASCEND-1 trial.. Journal of Clinical Oncology. 32(15_suppl). 8078–8078. 11 indexed citations

Goy, André, Steven H. Bernstein, Alice McDonald, et al.. (2010). Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trial. Leukemia & lymphoma. 51(7). 1269–1277. 19 indexed citations

Fidias, Panos, Nathan A. Pennell, Anthony Boral, et al.. (2009). Phase I Study of the c-raf-1 Antisense Oligonucleotide ISIS 5132 in Combination with Carboplatin and Paclitaxel in Patients with Previously Untreated, Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 4(9). 1156–1162. 17 indexed citations

10.

Vogl, Dan T., Edward A. Stadtmauer, Paul G. Richardson, et al.. (2009). Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma. British Journal of Haematology. 147(4). 531–534. 25 indexed citations

11.

Richardson, Paul G., Pieter Sonneveld, Michael W. Schuster, et al.. (2009). Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose‐modification guideline. British Journal of Haematology. 144(6). 895–903. 232 indexed citations

12.

Miguel, Jesús F. San, Paul G. Richardson, Pieter Sonneveld, et al.. (2008). Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia. 22(4). 842–849. 130 indexed citations

13.

Niesvizky, Rubén, Paul G. Richardson, S. Vincent Rajkumar, et al.. (2008). The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. British Journal of Haematology. 143(1). 46–53. 73 indexed citations

14.

Goy, André, Steven H. Bernstein, Brad S. Kahl, et al.. (2008). Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Annals of Oncology. 20(3). 520–525. 243 indexed citations

15.

Sezer, Orhan, David H. Vesole, Seema Singhal, et al.. (2006). Bortezomib-Induced Tumor Lysis Syndrome in Multiple Myeloma. Clinical Lymphoma & Myeloma. 7(3). 233–235. 42 indexed citations

16.

Gerecitano, John F., André Goy, James R. Wright, et al.. (2006). Drug‐induced cutaneous vasculitis in patients with non‐Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response?. British Journal of Haematology. 134(4). 391–398. 36 indexed citations

17.

Richardson, Paul G., Pieter Sonneveld, M. Schuster, et al.. (2005). Bortezomib Continues Demonstrates Superior Efficacy Compared with High-Dose Dexamethasone in Relapsed Multiple Myeloma: Updated Results of the APEX Trail.. Blood. 106(11). 2547–2547. 32 indexed citations

18.

Richardson, Paul G., Pieter Sonneveld, M. Schuster, et al.. (2004). Bortezomib Demonstrates Superior Efficacy to High-Dose Dexamethasone in Relapsed Multiple Myeloma: Final Report of the APEX Study.. Blood. 104(11). 1479–1479. 14 indexed citations

19.

Chabner, Bruce A., Anthony Boral, & Pratik S. Multani. (1998). Translational research: walking the bridge between idea and cure--seventeenth Bruce F. Cain Memorial Award lecture.. PubMed. 58(19). 4211–6. 37 indexed citations

20.

Boral, Anthony, Scott Dessain, & Bruce A. Chabner. (1998). Clinical evaluation of biologically targeted drugs: Obstacles and opportunities. Cancer Chemotherapy and Pharmacology. 42(S1). S3–S21. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact